From €123EUR$129USD£103GBP
- Report
- November 2021
- 527 Pages
Global
From €3818EUR$4,000USD£3,199GBP
- Report
- November 2021
- 545 Pages
Global
From €3818EUR$4,000USD£3,199GBP
- Report
- November 2021
- 802 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- November 2021
- 1184 Pages
Global
From €5726EUR$6,000USD£4,798GBP
- Report
- November 2021
- 1165 Pages
Global
From €5726EUR$6,000USD£4,798GBP
- Report
- August 2022
- 322 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- March 2022
- 286 Pages
Global
From €3298EUR$3,456USD£2,764GBP
- Book
- January 2019
- 504 Pages
- Book
- August 2014
- 240 Pages
- Book
- August 2022
- 304 Pages
- Book
- June 2022
- 336 Pages
- Book
- May 2022
- 512 Pages
- Book
- January 2022
- 336 Pages
- Book
- September 2019
- 1224 Pages
- Book
- September 2024
- 304 Pages
- Book
- February 2024
- 160 Pages
- Book
- November 2023
- 304 Pages
- Book
- May 2013
- 384 Pages
- Book
- September 2012
- 688 Pages

Epigenetics is a field of genomics that studies the regulation of gene expression without altering the underlying DNA sequence. It is a rapidly growing field of research that has the potential to revolutionize the understanding of gene regulation and its role in disease. Epigenetics is the study of how environmental factors, such as diet, lifestyle, and exposure to toxins, can affect gene expression. It is also used to study the effects of aging and the development of cancer.
Epigenetics has become an important tool in the diagnosis and treatment of many diseases, including cancer, diabetes, and neurological disorders. It is also being used to develop new therapies and treatments for a variety of diseases.
The epigenetics market is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and the development of new technologies. Companies in the epigenetics market include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Merck KGaA, and PerkinElmer. Show Less Read more